- These cells work by signalling. They release growth factors and messenger vesicles that calm inflammation, build new blood supply and switch your own repair cells back on.
- Two routes, two purposes. Targeted injection rebuilds a specific joint, tendon or disc. IV delivery works systemically on inflammation, recovery and whole-body regeneration.
- Placement decides the result. Every injection we perform is image-guided, because a product that does not reach the target cannot do anything.
- The terrain decides the result too. We correct inflammation, insulin and nutrient status first, because cells delivered into a hostile environment underperform.
- This is what regenerative medicine was supposed to be — not managing a symptom indefinitely, but giving the tissue what it needs to rebuild.
What these cells actually do
What I explain to every patient is that this is not about replacing tissue. It is about restarting a repair process that stalled.
Mesenchymal cells are your body's repair coordinators. When you were younger you had more of them and they responded faster, which is why a twenty-year-old recovers from an injury in weeks and the same injury at fifty becomes a permanent feature.
What these cells do is signal. They release growth factors, cytokines and extracellular vesicles that transform the environment around damaged tissue. Specifically, they:
- Calm the inflammatory signalling that keeps tissue in a state of chronic irritation and prevents it from ever finishing repair.
- Trigger angiogenesis — new blood vessel growth into tissue that had lost its supply. Cartilage, tendon and disc are poorly vascularised, which is precisely why they heal so badly on their own.
- Recruit and activate your own resident repair cells, which are still there and still capable, and simply are not receiving the instruction.
- Modulate the immune response locally, shifting it out of the destructive pattern and into a constructive one.
Many researchers now describe them as medicinal signalling cells for exactly this reason. I find that a more useful name, because it tells you what actually happens: you are not buying replacement parts, you are restoring a conversation your body used to have with itself.
Targeted injection or IV — and why both exist
These are two genuinely different treatments that happen to use the same biology, and the right one depends entirely on what you are trying to change.
Targeted injection is what we reach for when the problem has an address. A knee that has been painful for three years. A shoulder that will not settle. A tendon that has failed every other approach. Delivered under ultrasound guidance directly into the structure, the concentration at the site is enormously higher than anything systemic delivery could achieve.
IV delivery is for the person whose problem is everywhere. Inflammatory load that will not come down. Recovery capacity that has collapsed. The patient who is not injured so much as worn out. Here the signalling molecules distribute systemically and work on the environment rather than on one structure.
And in a meaningful number of cases we do both, because the joint that will not heal is frequently sitting in a body that is inflamed. Treat only the joint and you are working against the tide.
What makes the difference in outcomes
What I have seen clinically is that the same cells produce very different outcomes depending on three things that most clinics never address.
1. We prepare the terrain first
This is the one almost nobody does, and in my experience it matters more than anything else. Regenerative cells delivered into a body with high inflammatory markers, elevated insulin and depleted nutrients are being asked to rebuild in a hostile environment.
So before anything is injected or infused the full picture matters — hs-CRP, fasting insulin, ferritin, vitamin D, homocysteine and the rest — and correct what needs correcting. Vitamin D and zinc for tissue repair. Protein sufficient to build with. Inflammation brought down so the signal is not shouting into a storm. Patients who arrive prepared get a different result from patients who simply arrive.
2. Every injection is image-guided
A regenerative product placed near a structure rather than in it cannot do its job. Ultrasound guidance on every injection is what ensures the material reaches the tissue we intend to treat. This sounds obvious. It is not universal.
3. It works best combined with what accelerates it
Regenerative therapy works better alongside the things that improve oxygen delivery and cellular energy. Hyperbaric oxygen drives oxygen into tissue that has poor blood supply, which is exactly the tissue we are asking to rebuild. Red light therapy raises mitochondrial output in the cells doing the building. Peptides such as BPC-157 support the same repair pathways from a different direction.
Being a full clinic rather than an injection service means we can sequence all of that around one treatment. That is the difference between a procedure and a protocol.
The ten things regenerative therapy is used for most
Ranked by how directly the mechanism applies and how consistently we see patients respond.
Knee Osteoarthritis and Joint Degeneration
The most common reason people come to us for this, and the application with the strongest research behind it. Randomised work on intra-articular mesenchymal cells in knee osteoarthritis has shown improvements in pain and function that hold at follow-up. For a patient who has been told the only remaining option is replacement, this is a genuinely different conversation.
What the evidence showsJo and colleagues published a proof-of-concept trial of intra-articular mesenchymal cell injection in knee osteoarthritis in Stem Cells, reporting improvements in pain and function alongside cartilage changes on imaging.Tendon and Ligament Injury
Rotator cuff, tennis elbow, Achilles, plantar fascia, hamstring. These tissues heal badly because they have almost no blood supply — and building new blood supply is precisely what regenerative signalling does. This is where I have seen some of the most striking recoveries.
What the evidence showsTendon and ligament heal poorly because they are sparsely vascularised. Mesenchymal cells release VEGF and other angiogenic factors, addressing the specific limitation that makes these tissues slow to repair.Back Pain and Disc Degeneration
The disc is the least vascularised structure in the body, which is why disc problems become chronic. Delivered accurately, regenerative therapy addresses the environment rather than simply blocking the pain signal, and for the right patient it changes the trajectory.
What the evidence showsThe intervertebral disc is the largest avascular structure in the body, receiving nutrition only by diffusion. This is the mechanistic basis for degeneration becoming chronic and for regenerative approaches targeting the environment.Systemic Inflammation — IV
This is where intravenous delivery earns its place. Where inflammatory markers have been elevated for years and nothing has brought them down, systemic regenerative signalling works on the whole environment rather than one structure. We track hs-CRP so the effect is measured rather than assumed.
What the evidence showsMesenchymal cells modulate inflammatory signalling through paracrine secretion of anti-inflammatory cytokines and extracellular vesicles. Wang and colleagues reviewed the immunomodulatory mechanisms in Stem Cells International.Avoiding or Delaying Surgery
A great many patients arrive having been told surgery is the only option left. It sometimes is. But for a meaningful number, restoring the tissue's ability to repair changes what is necessary — and that decision deserves to be made after regenerative options have been tried rather than before.
What the evidence showsLee and colleagues conducted a phase IIb randomised placebo-controlled trial of adipose-derived mesenchymal cells in knee osteoarthritis, published in Stem Cells Translational Medicine, reporting improved function and cartilage outcomes.Recovery and Athletic Performance
Hard training creates micro-damage that has to be repaired, and repair capacity declines with age. Athletes and active people in their forties and fifties use regenerative therapy to keep training at an intensity their recovery would otherwise no longer support.
What the evidence showsRegenerative capacity declines with age as resident progenitor populations diminish and their responsiveness falls. This decline is one reason the same injury resolves in weeks at twenty and persists at fifty.Post-Surgical Healing
Where surgery has happened, regenerative support afterwards helps the tissue rebuild properly rather than simply closing. Combined with hyperbaric oxygen, this is one of the most useful recovery protocols available.
What the evidence showsPost-surgical healing depends on angiogenesis and controlled inflammatory resolution — the two processes mesenchymal signalling most directly influences. Combination with hyperbaric oxygen addresses tissue oxygenation simultaneously.Autoimmune and Immune Modulation
Mesenchymal cells modulate immune signalling rather than suppressing it, which is the distinction that matters in autoimmunity. Delivered systemically and alongside your specialist, this is an area of genuine and growing clinical interest.
What the evidence showsMesenchymal cells shift macrophage populations from inflammatory M1 toward reparative M2 phenotype, which is the mechanistic basis for immunomodulatory rather than immunosuppressive effects.Skin, Hair and Aesthetic Regeneration
The same growth factors that rebuild a tendon rebuild collagen. Applied to skin and scalp, regenerative products support collagen density, texture and hair follicle activity — and results here tend to be visible.
What the evidence showsThe growth factors driving tendon and cartilage repair also stimulate dermal fibroblast collagen synthesis, which is why the same signalling applies to skin and follicle applications.Healthy Aging and Longevity
Regenerative capacity declining is one of the defining features of ageing. Restoring the signal that tells tissue to repair is about as upstream as an intervention gets, and it is one of the most exciting areas in the whole of medicine right now.
What the evidence showsCaplan argued in Stem Cells Translational Medicine that these cells should be renamed medicinal signalling cells, because their therapeutic effect derives from secreted trophic and immunomodulatory factors rather than differentiation into replacement tissue.What people commonly experience with this therapy
When patients receive the proper guidance, here is what people commonly experience with it.
- The first week — a settling period. Localised injections often produce increased soreness for a few days as the repair response gets underway. That is the treatment working, and knowing to expect it makes it far easier to sit through.
- Weeks 2–4 — the first real change. Reduced pain and better movement in the treated area. With IV delivery, patients typically describe better energy and a general reduction in the aching that had become background noise.
- Weeks 4–12 — the main effect. Tissue remodelling takes time by nature, and this is the window where it shows. Function improves, range of motion returns, and patients start doing things they had quietly stopped doing.
- Months 3–12 — it holds. This is what makes regenerative work different from managing a symptom. Where the tissue genuinely rebuilds, the improvement tends to stay — and we reassess function, pain and inflammatory markers along the way.
If you have been told to live with it, manage it, or wait until it is bad enough for surgery, I would like you to have another conversation before you accept that. Schedule a consultation and let my team look at what is actually driving the problem and whether regenerative therapy can rebuild what you thought was permanent. You will be cared for by a team who will not stop until the root cause of every one of your health issues has been found and addressed.
We look at the joint and the whole body behind it, prepare the terrain properly, and tell you exactly what regenerative therapy can do for your case.
Common questions
What does stem cell therapy do?
Regenerative cells work by signalling. They release growth factors and messenger vesicles that calm inflammatory signalling, trigger new blood vessel growth into poorly supplied tissue, and activate the repair cells already present in the area. The result is that tissue which had stalled in a chronic state of irritation is able to rebuild.
Do you offer stem cell injections and IV therapy near Nashville?
Yes, both. We are at 329 S. Royal Oaks Blvd in Franklin, about twenty minutes south of downtown Nashville and minutes from Brentwood and Cool Springs. Image-guided injections target specific joints, tendons and discs, while intravenous regenerative therapy works systemically for systemic inflammation and whole-body recovery.
What is the difference between a stem cell injection and an IV?
Purpose. An injection delivers a very high concentration directly into one structure — a knee, a shoulder, a disc — under ultrasound guidance. An IV distributes the signalling systemically and works on the whole inflammatory environment rather than one site. We often use both together, because a joint that will not heal is frequently sitting in a body that is inflamed.
How long does it take to work?
There is usually a settling period of a few days after an injection as the repair response begins. Most patients notice meaningful change between weeks two and four, and the main effect develops across four to twelve weeks as tissue remodels. Where it works well, the improvement tends to hold rather than fade.
What makes your approach different?
Three things. We prepare the terrain first — inflammatory markers, insulin, vitamin D, protein status — because cells delivered into a hostile environment underperform. Image guidance is what ensures the material reaches the target. And it is best sequenced alongside supportive therapies rather than used alone, which accelerate the same repair pathways from different directions.
Is it painful?
The injection itself takes a few minutes and is done under local anaesthetic. Most patients describe pressure rather than pain. There is commonly increased soreness in the treated area for two to four days afterwards, which is the repair response getting underway and settles on its own. IV delivery is comfortable throughout.
- Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Translational Medicine. 2017;6(6):1445–1451. PMC5689741
- Jo CH, Lee YG, Shin WH, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells. 2014;32(5):1254–1266.
- Lee WS, Kim HJ, Kim KI, Kim GB, Jin W. Intra-articular injection of autologous adipose tissue-derived mesenchymal stem cells for the treatment of knee osteoarthritis: a phase IIb, randomized, placebo-controlled clinical trial. Stem Cells Translational Medicine. 2019;8(6):504–511. PMC6525563
- Wang M, Yuan Q, Xie L. Mesenchymal stem cell-based immunomodulation: properties and clinical application. Stem Cells International. 2018;2018:3057624.
- Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells. 2017;35(4):851–858.
This article is educational and reflects the published literature as of August 2026. It is not a diagnosis or a treatment recommendation for any individual, and any decision about your care belongs in a conversation with a licensed practitioner who has seen your history and your labs.